Literature DB >> 10854805

Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.

J Murakami1, K Kishi, K Hirai, K Hiramatsu, T Yamasaki, M Nasu.   

Abstract

We investigated the effects of antimicrobial agents fosfomycin (FOS), cefdinir (CDIN), levofloxacin (LEVX), rokitamycin (ROK), roxithromycin (ROX), and clindamycin (CLI) on the release of Shiga-like toxins (SLTs) by enterohaemorrhagic Escherichia coli (EHEC). EHEC was cultured for 14 h in the presence of ROX, ROK or CLI at sub-minimum inhibitory concentrations (subMICs) of 1.56-6.25 mg/l, followed by assay of the level of SLTs in the supernatants using cytotoxicity assay and reversed passive latex agglutination method. Exposure to ROX, ROK or CLI reduced the amount of released SLTs compared with untreated control cultures (P<0.05). These agents however, did not decrease the number of viable EHEC, indicating the importance of bactericidal agents. When the bacteria was exposed to CDIN, FOS or LEVX, the level of SLTs in the culture supernatant increased with the destruction of bacterial cells in the order of CDIN, FOS, LEVX. When 0.5 mg/l of LEVX was added to cultures with or without pretreatment using ROX, ROK, or CLI, the release of SLTs was reduced by this pretreatment (P<0.05). These results may have clinical implications for the treatment of EHEC infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854805     DOI: 10.1016/s0924-8579(00)00126-6

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Authors:  Malene Gantzhorn Pedersen; Claus Hansen; Erik Riise; Søren Persson; Katharina E P Olsen
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

2.  Genotypic and phenotypic profiles of virulence factors and antimicrobial resistance of Proteus mirabilis isolated from chicken carcasses: potential zoonotic risk.

Authors:  Matheus Silva Sanches; Ana Angelita Sampaio Baptista; Marielen de Souza; Maísa Fabiana Menck-Costa; Vanessa Lumi Koga; Renata Katsuko Takayama Kobayashi; Sergio Paulo Dejato Rocha
Journal:  Braz J Microbiol       Date:  2019-05-03       Impact factor: 2.476

3.  Different classes of antibiotics differentially influence shiga toxin production.

Authors:  Colleen Marie McGannon; Cynthia Ann Fuller; Alison Ann Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Proteus mirabilis causing cellulitis in broiler chickens.

Authors:  Matheus Silva Sanches; Ana Angelita Sampaio Baptista; Marielen de Souza; Maísa Fabiana Menck-Costa; Larissa Justino; Erick Kenji Nishio; Alexandre Oba; Ana Paula Frederico Rodrigues Loureiro Bracarense; Sergio Paulo Dejato Rocha
Journal:  Braz J Microbiol       Date:  2020-02-17       Impact factor: 2.476

5.  Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.

Authors:  Theresa J Ochoa; Jane Chen; Christopher M Walker; Elsa Gonzales; Thomas G Cleary
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

Review 6.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

7.  Survival and replication of Escherichia coli O157:H7 inside the mice peritoneal macrophages.

Authors:  Ayman Al-Mariri
Journal:  Braz J Microbiol       Date:  2008-03-01       Impact factor: 2.476

8.  Identification of diarrheagenic Escherichia coli strains from avian organic fertilizers.

Authors:  Juan Puño-Sarmiento; Luis Eduardo Gazal; Leonardo P Medeiros; Erick K Nishio; Renata K T Kobayashi; Gerson Nakazato
Journal:  Int J Environ Res Public Health       Date:  2014-08-28       Impact factor: 3.390

9.  In vitro growth-inhibitory effects of Portulaca oleracea L. formulation on intestinal pathogens.

Authors:  Sae Okuda; Takeaki Wajima; Tetsuya Yamada; Hidemasa Nakaminami; Hideaki Ikoshi; Norihisa Noguchi
Journal:  Access Microbiol       Date:  2021-02-24

Review 10.  Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Authors:  Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.